Illumina/$ILMN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Ticker
$ILMN
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
9,000
Website
Illumina Metrics
BasicAdvanced
$17B
-
-$6.08
1.36
-
Price and volume
Market cap
$17B
Beta
1.36
52-week high
$156.66
52-week low
$68.70
Average daily volume
2.4M
Financial strength
Current ratio
1.856
Quick ratio
1.344
Long term debt to equity
85.726
Total debt to equity
110.093
Interest coverage (TTM)
5.81%
Profitability
EBITDA (TTM)
956
Gross margin (TTM)
68.62%
Net profit margin (TTM)
-22.27%
Operating margin (TTM)
13.40%
Effective tax rate (TTM)
-8.78%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
4.95%
Return on equity (TTM)
-23.85%
Valuation
Price to revenue (TTM)
3.946
Price to book
7.23
Price to tangible book (TTM)
17.52
Price to free cash flow (TTM)
19.695
Free cash flow yield (TTM)
5.08%
Free cash flow per share (TTM)
546.54%
Growth
Revenue change (TTM)
-3.47%
Earnings per share change (TTM)
-25.41%
3-year revenue growth (CAGR)
-2.34%
10-year revenue growth (CAGR)
8.16%
3-year earnings per share growth (CAGR)
10.10%
10-year earnings per share growth (CAGR)
7.71%
What the Analysts think about Illumina
Analyst ratings (Buy, Hold, Sell) for Illumina stock.
Bulls say / Bears say
Illumina's acquisition of SomaLogic for $350 million is expected to enhance its presence in the proteomics market and advance its multiomics strategy, potentially driving future growth. (stocktitan.net)
The successful launch and adoption of the NovaSeq X and NovaSeq X Plus systems, which significantly increase sequencing capacity, position Illumina to meet growing demand in genomic research. (wikipedia.org)
Analyst upgrades, such as HSBC Global Research raising Illumina to a 'strong-buy' rating with a $180 price target, reflect confidence in the company's strategic direction and financial performance. (americanbankingnews.com)
Illumina's inclusion on China's 'Unreliable Entities List' and subsequent export restrictions could negatively impact its operations and revenue in the Chinese market. (nasdaq.com)
The European Commission's order to divest Grail within twelve months, along with a €432 million penalty for closing the acquisition without approval, may lead to financial and operational challenges. (wikipedia.org)
Activist investor Carl Icahn's lawsuit against Illumina's board and former CEO over the Grail acquisition raises concerns about corporate governance and potential legal liabilities. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Illumina Financial Performance
Revenues and expenses
Illumina Earnings Performance
Company profitability
Illumina News
AllArticlesVideos
Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling
Business Wire·1 month ago
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
Business Wire·2 months ago
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Illumina stock?
Illumina (ILMN) has a market cap of $17B as of July 25, 2025.
What is the P/E ratio for Illumina stock?
The price to earnings (P/E) ratio for Illumina (ILMN) stock is 0 as of July 25, 2025.
Does Illumina stock pay dividends?
No, Illumina (ILMN) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Illumina dividend payment date?
Illumina (ILMN) stock does not pay dividends to its shareholders.
What is the beta indicator for Illumina?
Illumina (ILMN) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.